A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
- Conditions
- Part 2：B-cell MalignanciesPart 1：r/r B-cell Malignancies
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04014205
- Locations
- 🇺🇸
Los Angeles Cancer Network - Good Samaritan Hospital Location, Los Angeles, California, United States
🇺🇸Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇺🇸University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT03797456
- Locations
- 🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Clinical Study of ICP-192 in Solid Tumors Patients
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03758664
- Locations
- 🇨🇳
Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Hunan cancer hospital & the affiliated cancer hospital of xiangya school of medicine ,central south university, Changsha, Hunan, China
Study of ICP-105 in Solid Tumors Patients
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03642834
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03494179
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03493217
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China